BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Fuisz International Pharma Announces Acquisition of Key Anti Opiate Abuse Patent to Complement its Anti Opiate Abuse Platform


7/12/2010 12:01:18 PM

MIAMI, July 12 /PRNewswire/ -- Fuisz Pharma today announced that it has acquired a key issued patent (US 7,214,385 "Pharmaceutical Formulation Containing Dye" (invented by Dr. Thomas Gruber)). This patent covers the use of dyes and staining agents in pharmaceutical dosage forms as a method to prevent the improper use of opiate derived drugs by visually demonstrating their misuse.

Fuisz Pharma President, Joseph Matus Fuisz commented: "The technology described in the acquired patent is highly complementary to the anti abuse portfolio that we previously announced. Importantly, the Gruber patent enables us to offer strong, existing patent protection for our partners. We thus believe that this acquisition significantly enhances the value of our anti abuse platform and gives us a very strong IP position in the prevention of opiate abuse."

Mr. Fuisz continued: "This acquisition is also complementary to our next generation technology to aid and abet the absorption of all dosage forms including the ability to bring forth a very novel methodology to specifically play a critical role in the opiate agonist/antagonist pas de deux. This methodology is applicable to all dosage forms."

Noted pharmaceutical inventor Richard C. Fuisz, M.D. (http://en.wikipedia.org/wiki/Richard_Carl_Fuisz) is one of the principals of Fuisz Pharma.

Fuisz Pharma is a private pharmaceutical technology company originated by the Fuiszes. The Fuiszes have made substantial contributions in drug delivery including orally dissolving tablets and novel particle coating systems at Fuisz Technologies; inventing and developing thin film drug delivery technologies at Kosmos Pharma and MonoSol Rx, as well as independently developing extruded sheet technology, and have extensive experience working with big and specialty pharma. Fuisz Pharma has its headquarters in Miami. www.fuisz.com.

SOURCE Fuisz Pharma



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES